Pere Fontova

Dr. Pere Fontova


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2017 in The FEBS Journal
Verified
Journal Article
Closed access
PDF file
ARAna Rodríguez‐García
Ana Rodríguez‐García
PSPaula Samsó
Paula Samsó
PFPere Fontova
Pere Fontova
HSHelga Simon-Molas
Helga Simon-Molas
ACAnna Manzano Cuesta
Anna Manzano Cuesta
RBRamon Bartrons
Ramon Bartrons

28 June 2023 in Kidney International
Verified
Journal Article
Closed access
NLNúria Lloberas
Núria Lloberas
JGJosep M. Grinyó
Josep M. Grinyó
Helena ColomHelena Colom
Helena Colom
AVAnna Vidal-Alabró
Anna Vidal-Alabró
PFPere Fontova
Pere Fontova
JCJosep M. Cruzado
Josep M. Cruzado

12 February 2018 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
HSHelga Simon-Molas
Helga Simon-Molas
CAClaudia Arnedo-Pac
Claudia Arnedo-Pac
PFPere Fontova
Pere Fontova
AVAnna Vidal-Alabró
Anna Vidal-Alabró
ECEsther Castaño
Esther Castaño
RBRamon Bartrons
Ramon Bartrons

1 June 2018 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
CHCristina El Haj
Cristina El Haj
Óscar MurilloÓscar Murillo
Óscar Murillo
ARAlba Ribera
Alba Ribera
NLNuria Lloberas
Nuria Lloberas
JGJoan Gómez-Junyent
Joan Gómez-Junyent
JAJavier Ariza
Javier Ariza

26 October 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
IRInes Rama
Ines Rama
ILInes Llaudó
Ines Llaudó
PFPere Fontova
Pere Fontova
GCGema Cerezo
Gema Cerezo
CSCarlos Soto
Carlos Soto
NLNúria Lloberas
Núria Lloberas
Patients undergoing conventional hemodialysis (C-HD) present a greater immuno-inflammatory state probably related to uremia, sympathetic nervous system (SNS) activation and /or membrane bioincompatibility, which could improve with a technique-switching to online hemodiafiltration (OL-HD). The antigen-independent pathway activation of this modified immunologic state turns dendritic cells (DC) into an accurate cell model to study these patients. The aim of this study is to further evaluate the immune-inflammatory state of patients in C-HD assessed by DC maturation. 31 patients were submitted to C-HD and after 4 months switched to the OL-HD technique. Monocytes-derived DCs from HD patients were cultured in the presence of IL-4/GM-CSF. DC-maturation was evaluated by assessing the maturation phenotype by flow cytometry (FACs). DCs-functional capacity to elicit T-cell alloresponse was studied by mixed leucocyte reaction. Cytokine release was assessed by FACs and SNS was evaluated measuring renalase levels by ELISA. An up-regulation of maturation markers was observed in C-HD DCs which induced two fold more T cells proliferation than OL-HD DCs. Also, C-HD-mDCs presented with over-production of pro-inflammatory cytokines (IL-6, IL-1β, IL-8, IL-10 and TNF-α) compared with OL-HD-mDC (P<0·05). Results were correlated with clinical data. When SNS was evaluated, hypotension events and blood pressure were significantly lower and renalase levels were significantly higher after conversion to OL-HD. Diabetes mellitus type 2 patients also found beneficial reduction of mDC when converted to OL-HD compared to non-diabetics. OL-HD could interfere with immuno-inflammatory state in HD patients with an improvement of renalase levels as potential key mediators in the mechanistic pathway of down-regulation of DC maturation.

29 November 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ZAZeyar Mohammed Ali
Zeyar Mohammed Ali
MMMarinda Meertens
Marinda Meertens
BFBeatriz Fernández-Alarcón
Beatriz Fernández-Alarcón
PFPere Fontova
Pere Fontova
AVAnna Vidal-Alabró
Anna Vidal-Alabró
NLNúria Lloberas
Núria Lloberas
The aim of the study is to develop a population pharmacokinetic (PopPK) model and to investigate the influence of CYP3A5/CYP3A4 and ABCB1 single nucleotide polymorphisms (SNPs) on the Tacrolimus PK parameters after LCP-Tac formulation in stable adult renal transplant patients. The model was developed, using NONMEM v7.5, from full PK profiles from a clinical study (n = 30) and trough concentrations (C0) from patient follow-up (n = 68). The PK profile of the LCP-Tac formulation was best described by a two-compartment model with linear elimination, parameterized in elimination (CL/F) and distributional (CLD/F) clearances and central compartment (Vc/F) and peripheral compartment (Vp/F) distribution volumes. A time-lagged first-order absorption process was characterized using transit compartment models. According to the structural part of the base model, the LCP-Tac showed an absorption profile characterized by two transit compartments and a mean transit time of 3.02 h. Inter-individual variability was associated with CL/F, Vc/F, and Vp/F. Adding inter-occasion variability (IOV) on CL/F caused a statistically significant reduction in the model minimum objective function MOFV (p < 0.001). Genetic polymorphism of CYP3A5 and a cluster of CYP3A4/A5 SNPs statistically significantly influenced Tac CL/F. In conclusion, a PopPK model was successfully developed for LCP-Tac formulation in stable renal transplant patients. CYP3A4/A5 SNPs as a combined cluster including three different phenotypes (high, intermediate, and poor metabolizers) was the most powerful covariate to describe part of the inter-individual variability associated with apparent elimination clearance. Considering this covariate in the initial dose estimation and during the therapeutic drug monitoring (TDM) would probably optimize Tac exposure attainments.